来氟米特治疗难治性肾病综合征52例临床观察

目的:观察长程应用来氟米特联合泼尼松治疗难治性肾病综合征患者的疗效和安全性.方法:将52例难治性肾病综合征患者随机分为治疗组26例和对照组26例,治疗组采用中等量激素联合来氟米特治疗,对照组采用中等量激素联合环磷酰胺(CTX)冲击治疗,观察两组临床指标变化和不良反应,随访时间12个月.结果:治疗组治疗后24 h尿蛋白定量显著减少P<0.05),血清白蛋白显著升高(P<0.05),完全缓解率46.15%,总有效率80.76%.与对照组比完全缓解率差异有显著性(P<0.05),治疗组12周内显效率高于对照组(P<0.05),不良反应轻微,所有患者耐受性良好.结论:来氟米特能够有效缓解难治性肾病综合征.

Clinical trial on the effect of leflunomide in treating refractory nephropathy syndrome

Objective:It was to observe the clinical curative effect of leflunomide as a new immune suppressive agent in refractory nephropathy syndrome.Methods:52 refractory nephropathy patients in our hospital from 2002 to 2007 were divided into two groups at random,with 26 cases in each group.Patients in test group received leflunomide and medium amount hormone,while patients in control group received CTX and medium amount hormone.The clinical data were observed in the 2nd,4th,6th,8th,12th,16th,20th,24th and 28th week.Results:In the test group,the proteinuria was decreased significantly(P<0.05);the serum albumin was increased significantly(P<0.05);complete relieving rate was 46.15%,and total effective rate was 80.76%.Compared with CTX group,the complete relieving rate of leflunomide in treating refractory nephropathy syndrome was statistically different(P>0.05).The rate of showing efficacy in 12th week in Leflunomide group was higher than that in CTX group(P<0.05),side effects were mild.All patients could tolerate this therapy.Conclusion:Leflunomide is a safe and effective medicine in treating refractory nephropathy syndrome.